Neimeth International Pharmaceuticals Plc has recorded a strong third-quarter performance in 2025, with sales growing 62% to N5.01 billion, up from N3.09 billion in the same period last year. The growth underscores the company’s expanding business activities in the pharmaceutical sector.

The company’s gross profit rose 71% to N2.49 billion, while operating profit surged 120% to N1.66 billion, reflecting improved efficiency and strong revenue management.

Cost management remained a priority. Marketing and distribution expenses grew modestly by 6% to N437.4 million, whereas administrative costs rose 67%, influenced by inflation and foreign exchange fluctuations. However, a significant 198% increase in finance costs—from N442.7 million to N1.3 billion—limited bottom-line growth. As a result, net profit rose marginally by 9% to N339.8 million from N310.4 million in Q3 2024.

Neimeth’s balance sheet reflects continued expansion. Total assets grew to N13.35 billion from N11.99 billion at the end of 2024, while total liabilities increased to N11.35 billion. Net assets improved by 21% to N1.99 billion, supported by the period’s profits.

The company also reported robust operating cash flow, generating N1.5 billion during the nine-month period, although significant cash outflows of N1.42 billion were recorded for financing activities, largely due to finance cost payments.

Neimeth’s equity base strengthened, rising from N1.65 billion at the start of the period to N1.99 billion by September 2025. Earnings per share (EPS) increased to 7.95 kobo from 7.27 kobo in the comparable period of 2024.

The performance signals steady growth and resilience, positioning Neimeth for further expansion both locally and potentially into international markets.